Allspring Global Investments Holdings LLC Raises Stock Holdings in Cencora, Inc. $COR

Allspring Global Investments Holdings LLC raised its holdings in shares of Cencora, Inc. (NYSE:COR) by 7.8% in the first quarter, Holdings Channel.com reports. The firm owned 413,051 shares of the company’s stock after buying an additional 29,983 shares during the period. Allspring Global Investments Holdings LLC’s holdings in Cencora were worth $131,210,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Kemnay Advisory Services Inc. acquired a new position in shares of Cencora in the 4th quarter valued at approximately $25,000. Oakworth Capital Inc. acquired a new stake in shares of Cencora during the fourth quarter worth approximately $26,000. Elyxium Wealth LLC acquired a new stake in shares of Cencora during the fourth quarter worth approximately $27,000. Archer Investment Corp increased its stake in shares of Cencora by 134.3% in the fourth quarter. Archer Investment Corp now owns 82 shares of the company’s stock worth $28,000 after buying an additional 47 shares during the last quarter. Finally, Motiv8 Investments LLC bought a new stake in shares of Cencora in the fourth quarter worth $29,000. 97.52% of the stock is currently owned by hedge funds and other institutional investors.

Cencora Stock Performance

COR stock opened at $307.80 on Friday. The company has a current ratio of 0.95, a quick ratio of 0.59 and a debt-to-equity ratio of 3.40. The firm has a market cap of $59.88 billion, a P/E ratio of 23.60, a P/E/G ratio of 1.65 and a beta of 0.58. Cencora, Inc. has a 12-month low of $244.82 and a 12-month high of $377.54. The stock’s 50 day simple moving average is $279.05 and its 200 day simple moving average is $317.75.

Cencora (NYSE:COR) last announced its quarterly earnings data on Wednesday, May 6th. The company reported $4.75 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.82 by ($0.07). The firm had revenue of $78.36 billion for the quarter, compared to the consensus estimate of $81.09 billion. Cencora had a return on equity of 135.20% and a net margin of 0.78%.The business’s revenue for the quarter was up 3.9% compared to the same quarter last year. During the same quarter last year, the business earned $4.42 earnings per share. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. As a group, equities research analysts predict that Cencora, Inc. will post 17.79 EPS for the current year.

Cencora declared that its Board of Directors has initiated a share buyback program on Thursday, May 21st that allows the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization allows the company to buy up to 3.9% of its shares through open market purchases. Shares repurchase programs are usually a sign that the company’s leadership believes its stock is undervalued.

Cencora Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, June 1st. Stockholders of record on Friday, May 15th were given a $0.60 dividend. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.8%. The ex-dividend date was Friday, May 15th. Cencora’s dividend payout ratio (DPR) is presently 18.40%.

Insider Activity at Cencora

In other Cencora news, Director Lauren M. Tyler purchased 550 shares of the firm’s stock in a transaction dated Monday, June 22nd. The stock was acquired at an average cost of $270.23 per share, with a total value of $148,626.50. Following the acquisition, the director owned 4,359 shares of the company’s stock, valued at approximately $1,177,932.57. This represents a 14.44% increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 0.38% of the company’s stock.

Wall Street Analysts Forecast Growth

COR has been the topic of a number of research analyst reports. Wells Fargo & Company reduced their price objective on shares of Cencora from $429.00 to $331.00 and set an “overweight” rating on the stock in a research note on Monday, May 11th. Citigroup dropped their target price on shares of Cencora from $405.00 to $355.00 and set a “buy” rating for the company in a research report on Thursday, May 7th. Evercore set a $360.00 target price on shares of Cencora in a research note on Wednesday, April 8th. Bank of America increased their price target on shares of Cencora from $280.00 to $285.00 and gave the stock a “neutral” rating in a research report on Wednesday, June 24th. Finally, UBS Group lifted their price target on Cencora from $410.00 to $412.00 and gave the stock a “buy” rating in a research note on Thursday, May 7th. Eleven investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $367.75.

Cencora Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.